Literature DB >> 6516697

A neonatal mass-screening for congenital adrenal hyperplasia in Japan.

K Shimozawa, S Saisho, N Saito, J Yata, Y Igarashi, Y Hikita, M Irie, K Okada.   

Abstract

A pilot neonatal mass-screening for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) was performed in the western region of Shizuoka Prefecture, Japan, using a simplified radioimmunoassay method for 'Disc-17-hydroxyprogesterone (17-OHP) determination. The results obtained during a 30-month period indicated that 3 infants out of the 34314 neonates examined were proved to have 21-OHD, and the incidence of homozygotes and heterozygotes were estimated to be 1:11438 and 1:54, respectively. At the time of recall, the concentrations of plasma 17-OHP and 21-deoxycortisol and their urine metabolites as well as plasma sodium levels were quite applicable to diagnosis, while the clinical signs that may be manifest in 21-OHD were of little value in this connection. Prematurity and perinatal complications of neonates tended to give false-positive results, being secondary to the function of the residual foetal adrenal cortex and non-specific stimulatory effects of various stresses. Despite several technical and practical problems to be solved, the present study demonstrated the importance and validity of a neonatal mass-screening program for CAH.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6516697     DOI: 10.1530/acta.0.1070513

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  8 in total

1.  Review of CAH screening programmes and the Scottish experience.

Authors:  A M Wallace
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

2.  Clinical aspects of congenital adrenal hyperplasia: early diagnosis and prognosis.

Authors:  I A Hughes
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  Neonatal screening for congenital adrenal hyperplasia: a pilot study in France.

Authors:  J L Dhondt; C Dorche; J P Farriaux; C Courte
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

4.  Response to ACTH in the newborn.

Authors:  S Thomas; J F Murphy; J Dyas; M Ryalls; I A Hughes
Journal:  Arch Dis Child       Date:  1986-01       Impact factor: 3.791

5.  Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia.

Authors:  I Terai; K Yamano; N Ichihara; J Arai; K Kobayashi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

6.  Value of selective screening for congenital adrenal hyperplasia in Hungary.

Authors:  J Sólyom; I A Hughes
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

7.  Should we screen for congenital adrenal hyperplasia? A review of 117 cases.

Authors:  N K Virdi; P H Rayner; B T Rudd; A Green
Journal:  Arch Dis Child       Date:  1987-07       Impact factor: 3.791

8.  In Vitro Enzyme Assay of CYP21A2 Mutation (R483Q) by A Novel Method Using Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS).

Authors:  Makoto Ono; Kenichi Kashimada; Kentaro Miyai; Toshikazu Onishi; Masatoshi Takagi; Seijiro Honma; Shuki Mizutani
Journal:  Clin Pediatr Endocrinol       Date:  2008-05-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.